secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001558370-23-005110
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo reports FY2022 net loss $14.0M; cash $33.4M; pipeline shift to cardiometabolic
--------------------------------------------------------------------------------

- Net loss of $14.0M ($5.43 per share) vs $15.3M ($19.81 per share) in FY2021.
- Cash and equivalents $33.4M as of Dec 31, 2022, up from $16.4M; runway into 2024.
- R&D expenses fell to $2.8M from $6.5M due to reduced clinical activity and drug manufacturing.
- Pipeline focus: DA-1241 phase 2a NASH study starts Q3 2023; DA-1726 IND/phase 1a expected H1 2024.
- Legacy programs (ANA001, NB-01, NB-02, Gemcabene) to be licensed or acquired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/0001558370-23-005110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023005110/nrbo-20230330x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer